Clinic
Fast Lab Technologies LLC
Fast Lab Technologies LLC was paid $6.07M by Medicaid between Dec 2021 and Dec 2024, across 5 billing codes. Its largest line is 87811, Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) — 58% of everything it billed.
33Billing provider infoFAST LAB TECHNOLOGIES LLC
BROOKLYN, NY 11201
BROOKLYN, NY 11201
33aNPI1154089241assigned 12/06/2021
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$6.07M
24GClaims402,397
24DCodes billed5
24AFirst – last monthDec 2021 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in New York
Rank by total paid#16 of 118
Median peer was paid$372K
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 713 | $15K | |
| 2022 | 26,872 | $528K | |
| 2023 | 219,514 | $3.78M | |
| 2024incomplete | 155,298 | $1.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 58% | 277,260 | 70,448 | $3.55M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 18% | 62,149 | 48,673 | $1.11M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 16% | 21,697 | 5,888 | $942K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4.1% | 23,262 | 6,270 | $248K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.6% | 18,029 | 5,055 | $218K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBIRICIK, CEMHAN (CEO)